Theta Burst Stimulation (iTBS) Explained

Theta burst stimulation (TBS) is a form of TMS that delivers pulses in short, rapid bursts instead of a steady rhythm. The intermittent version, iTBS, gives a full depression treatment session in about 3 minutes, compared with roughly 19 to 37.5 minutes for standard 10 Hz rTMS. In the largest comparison, the 2018 THREE-D trial of 414 adults, iTBS was non-inferior to 10 Hz rTMS for treatment-resistant depression.

iTBS has been FDA-cleared for adult major depression since August 2018 and is rated a first-line protocol by Canada's CANMAT 2023 guideline. What it changes is session length, not the number of days: a standard iTBS course still runs daily over about six weeks. Insurance coverage is uneven, and several large U.S. payers still classify it as unproven.

The pattern: bursts within a rhythm

Standard rTMS for depression delivers pulses at 10 per second in 4-second trains separated by rest periods, 3,000 pulses in all. iTBS is structured differently. In the FDA-cleared MagVita protocol:

• Each burst is 3 pulses at 50 Hz, 20 milliseconds apart.
• Bursts repeat 5 times per second, which is the theta frequency that gives the method its name.
• A 2-second train of bursts is followed by 8 seconds of rest, and 20 trains make a session.
• The session delivers 600 pulses at 120% of motor threshold in 3 minutes and 9 seconds.

NeuroStar's own theta-burst mode uses the same burst structure and 600 pulses, at 80% to 120% of motor threshold, with a listed session length of 3.3 minutes. The word "intermittent" refers to the on-off trains. Continuous theta burst (cTBS) runs the bursts without breaks and, in motor-cortex studies, suppresses rather than facilitates cortical excitability.

Where it came from

TBS was developed in motor-cortex physiology rather than in depression research. In 2005, Huang and colleagues reported that theta-patterned bursts produced a "controllable, consistent, long-lasting, and powerful effect on motor cortex physiology" after only 20 to 190 seconds of stimulation.

A follow-up placebo-controlled study gave volunteers memantine, which blocks NMDA glutamate receptors. Memantine "blocked the suppressive effect of cTBS and the facilitatory effect of iTBS", evidence that the after-effects involve plasticity-like changes at synapses. That is part of the rationale for expecting a short iTBS session to do as much as a long rTMS one. The broader mechanism is covered in how TMS works.

The THREE-D trial

THREE-D, published in The Lancet in 2018, is the trial that made iTBS a standard treatment. Its design and results:

• 414 adults aged 18 to 65 with treatment-resistant depression at three Canadian hospitals were randomized to 10 Hz rTMS (205) or iTBS (209), 5 days a week for 4 to 6 weeks.
• Patients stayed on stable antidepressants. Treatment was open-label, but the raters were blinded.
• Hamilton depression scores fell from 23.5 to 13.4 with 10 Hz and from 23.6 to 13.4 with iTBS, meeting the pre-set non-inferiority margin.
• In the iTBS arm, 49% responded and 32% remitted, according to FDA's later summary of the trial.

Non-inferiority means iTBS was shown to be not meaningfully worse than 10 Hz. It does not mean iTBS is better. THREE-D also had no sham arm, so it shows the two protocols performed alike, not how much either beats placebo. FDA cleared the first iTBS protocol in August 2018, citing "a large randomized, multicenter trial".

What else the evidence shows

Other comparisons point the same way, with caveats:

• BRIGhTMIND (2024) compared connectivity-guided iTBS with MRI-navigated 10 Hz rTMS in 255 patients and found no difference over 26 weeks.
• A 2017 network meta-analysis of 81 trials found theta burst better than sham for response (odds ratio 2.54), but not significantly better for remission.
• A 2026 network meta-analysis of 141 trials ranked TBS highly for response (odds ratio 4.47 vs sham), but rated confidence in most comparisons low or very low, and only 3 trials were at low risk of bias.

Guidelines are not unanimous. CANMAT 2023 rates iTBS to the left DLPFC first-line with Level 1 evidence, the same rating as 10 Hz rTMS. The U.S. VA/DoD guideline from 2022 found "insufficient evidence to recommend for or against theta-burst stimulation". The difference partly reflects timing and the evidence each panel weighed.

Session time vs course length

A common misunderstanding is that iTBS shortens the whole treatment. In its standard form it shortens each visit, not the number of visits.

The time saved is real, though. A visit with a 3-minute stimulation can fit around a workday more easily, and clinics can treat more patients per device. Some accelerated protocols go further and stack several iTBS sessions into one day; these are explained in accelerated TMS and the SAINT protocol.

iTBS in accelerated and bilateral schedules

Because each iTBS session is short, it is the natural building block for accelerated courses that give several sessions a day. The evidence for that use is growing but less mature than for once-daily iTBS:

• A 2026 meta-analysis pooled 15 sham-controlled trials of accelerated iTBS (704 patients) and found response roughly doubled compared with sham (risk ratio 1.99), though only 46% of the trials were at low risk of bias.
• A 2025 triple-blind trial in Brazil gave 100 patients 45 sessions of iTBS, 3 a day over 15 weekdays, without neuronavigation. Response was 52% with active treatment vs 22% with sham.
• CANMAT 2023 rates accelerated iTBS to the left DLPFC second-line, with Level 3 evidence, a step below once-daily iTBS.

Theta burst can also be given to both sides of the prefrontal cortex in sequence, which CANMAT lists as second-line. These variations are why "theta burst" on a clinic's website can mean quite different treatments. Ask whether the plan is once-daily iTBS, an accelerated schedule or a bilateral protocol, and which of them is FDA-cleared on the device being used.

Common misconceptions

• "iTBS is a new, experimental TMS." It has been FDA-cleared for adult depression since 2018 and is rated first-line by CANMAT. Some insurers lag behind that status.
• "iTBS works faster." THREE-D was not designed to show faster improvement; it showed similar improvement over the same 4 to 6 week course.
• "Three minutes means a weaker treatment." Fewer pulses are delivered, but the burst pattern was designed to produce strong after-effects with less stimulation time.
• "iTBS and SAINT are the same thing." SAINT uses iTBS, but adds an MRI-derived individual target and 10 sessions a day for 5 days.

Comfort and side effects

Because the bursts are dense, iTBS can feel more intense moment to moment. In THREE-D, patients rated iTBS slightly more painful than 10 Hz, 3.8 vs 3.4 on a 10-point scale. Otherwise tolerability was similar: dropout was 8% with iTBS vs 6% with 10 Hz, and headache, the most common side effect, occurred in 65% vs 64%. Seizure is a rare risk with any form of TMS, and the same screening applies; see TMS safety and seizure risk.

For many patients, a few minutes of slightly sharper stimulation is a good trade for a much shorter visit. Others prefer the steadier rhythm of standard rTMS and do not mind the longer visit. If discomfort is a problem early in a course, intensity is sometimes started lower and increased over the first sessions, a decision for the treating team. The patient guide What does TMS feel like? describes the sensations.

Insurance coverage for iTBS

Coverage depends on the plan, and published policies disagree:

Because policies change, confirm before a course starts which protocol is being authorized. Plan details are in the guides to Aetna, Cigna and UnitedHealthcare and Optum.

Who iTBS suits

iTBS is a reasonable first choice of TMS protocol for many adults with depression who meet the usual criteria for TMS, particularly when time is the main barrier. Points to weigh with a psychiatrist:

• Insurance: if the plan treats iTBS as unproven, a 10 Hz course may be the practical route.
• Sensitivity to discomfort: iTBS was rated slightly more painful on average.
• Previous response: if a past course of one protocol worked, repeating it is a sensible default.
• Older adults: a 2026 trial of bilateral theta burst in 108 patients aged 60 and over missed its week-6 endpoint but showed benefit by week 12, so late-life depression may need patience or a different protocol.

The rest of the series is in the TMS guide, and the TMS therapy page describes TMS in the context of psychiatric care.

Frequently asked questions

Is theta burst TMS as effective as regular TMS?

In the THREE-D trial of 414 adults with treatment-resistant depression, iTBS was non-inferior to standard 10 Hz rTMS, with nearly identical improvement in depression scores. That means not meaningfully worse, not better.

Does iTBS mean fewer appointments?

Not in its standard form. Each session lasts about 3 minutes, but the course is still daily sessions over about six weeks. Only accelerated schedules, which stack several sessions into one day, shorten the overall course.

Is iTBS FDA-cleared?

Yes. The first iTBS protocol for adult major depression was cleared in August 2018, and several TMS systems now include a theta-burst mode.

Does theta burst hurt more than standard TMS?

Slightly, on average. THREE-D patients rated iTBS 3.8 out of 10 for pain vs 3.4 for 10 Hz rTMS, and dropout rates were similar.

What is the difference between iTBS and cTBS?

Intermittent theta burst (iTBS) delivers bursts in 2-second trains with rests and increases cortical excitability in motor-cortex studies. Continuous theta burst (cTBS) runs the bursts without breaks and decreases excitability. iTBS is the form used and cleared for depression.

Sources

1. K173620 510(k) Summary: MagVita TMS Therapy System w/Theta Burst Stimulation. U.S. FDA, 2018. accessdata.fda.gov
2. K231926 510(k) Summary: NeuroStar Advanced Therapy System. U.S. FDA, 2024. accessdata.fda.gov
3. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet, 2018. pubmed.ncbi.nlm.nih.gov
4. K220177 510(k) Summary: Magnus Neuromodulation System with SAINT Technology. U.S. FDA, 2022. accessdata.fda.gov
5. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry, 2010. pubmed.ncbi.nlm.nih.gov
6. Theta burst stimulation of the human motor cortex. Neuron, 2005. pubmed.ncbi.nlm.nih.gov
7. The after-effect of human theta burst stimulation is NMDA receptor dependent. Clinical Neurophysiology, 2007. pubmed.ncbi.nlm.nih.gov
8. Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial. Nature Medicine, 2024. pubmed.ncbi.nlm.nih.gov
9. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry, 2017. pubmed.ncbi.nlm.nih.gov
10. Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Journal of Evidence-Based Medicine, 2026. pubmed.ncbi.nlm.nih.gov
11. Accelerated intermittent theta-burst stimulation for major depressive episodes: systematic review and dose-response meta-analysis. Brain Stimulation, 2026. pubmed.ncbi.nlm.nih.gov
12. Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 2025. pmc.ncbi.nlm.nih.gov
13. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry, 2024. pmc.ncbi.nlm.nih.gov
14. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. U.S. Department of Veterans Affairs and Department of Defense, 2022. healthquality.va.gov
15. Bilateral Theta-Burst Stimulation of Dorsolateral Prefrontal Cortex Regions for Late-Life Depression: A Randomized, Sham-Controlled Clinical Trial. American Journal of Psychiatry, 2026. pubmed.ncbi.nlm.nih.gov
16. Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (Clinical Policy Bulletin 0469). Aetna, 2026. aetna.com
17. Transcranial Magnetic Stimulation (Coverage Policy EN0383). Evernorth Health Services (Cigna), 2026. a.static.cigna.com
18. Transcranial Magnetic Stimulation for Treating Physical Health Conditions (2026T0536W). UnitedHealthcare, 2026. uhcprovider.com
19. Behavioral Clinical Policy: Transcranial Magnetic Stimulation (BH803TMS112025). Optum Behavioral Health Solutions, 2026. providerexpress.com
20. Repetitive Transcranial Magnetic Stimulation (TMS) - Policy and Procedure (BMD-110). MetroPlusHealth, 2025. metroplus.org
21. LCD L33398 Transcranial Magnetic Stimulation (version 40). CMS Medicare Coverage Database (Wellpoint Federal), 2026. cms.gov

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.